(Total Views: 166)
Posted On: 12/16/2018 10:39:35 AM
Post# of 36570
Been wondering why the lack of sales also.
Joe doesn't seem to be a fan of Taxus Cardium(name change to Gene Biotherapeutics about a year ago) but yet is launching Excellagen (which Taxus Cardium/Gene Biotherapeutics sold partial rights to Olaregen quite recently). Now GNBT has bought, or in the process of buying a controlling interest in Olaregen.
Like yourself I am wondering why Excellagen has not been successfully marketed yet. We obviously wish GNBT the best in rolling it out through the pharmacy network etc. Maybe the hurdle was government bureaucracy related.
Joe doesn't seem to be a fan of Taxus Cardium(name change to Gene Biotherapeutics about a year ago) but yet is launching Excellagen (which Taxus Cardium/Gene Biotherapeutics sold partial rights to Olaregen quite recently). Now GNBT has bought, or in the process of buying a controlling interest in Olaregen.
Like yourself I am wondering why Excellagen has not been successfully marketed yet. We obviously wish GNBT the best in rolling it out through the pharmacy network etc. Maybe the hurdle was government bureaucracy related.
(0)
(0)
